TREM2 and early-onset autosomal dominant Alzheimer disease: Recently, an agonistic antibody targeting TREM2 (AL002; INVOKE-2 trial) was evaluated in patients with Alzheimer’s disease to test the therapeutic potential of modulating microglial function through the TREM2 pathway.